Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Golidocitinib combination therapy as first-line treatment in PTCL: Retrospective data from a single centre

Wenyu Li, Ling Huang Nov 03, 2025 pp. 6305-6305 10.1182/blood-2025-6305

Abstract Background: Peripheral T-cell lymphoma (PTCL), except for the anaplastic large cell lymphoma (ALCL) subtype, is characterized by a...

Matched unrelated vs. Haploidentical  donor for allogeneic stem cell transplantation in patients with acute leukemia with identical GvHD prophylaxis – a randomized prospective european trial.

Nicolaus Kroeger, Jaime Sanz, Matthias Stelljes et al. Nov 03, 2025 pp. 171-171 10.1182/blood-2025-171

Abstract Haplo-identical allogeneic cell transplantation (haploHCT) using post- transplant cyclophosphamide (PTCy) is increasingly used if n...

Novel AML specific splice junction evaluation identifies ubc and DMBT1 as top proteins of clinical and therapeutic relevance in pediatric Acute Myeloid Leukemia

Ryanne Mulligan, Alyssa Obermayer, Xiaotu Ma et al. Nov 03, 2025 pp. 3497-3497 10.1182/blood-2025-3497

Abstract Introduction: Acute Myeloid leukemia (AML) is a hematologic malignancy characterized by uncontrollable proliferation of myeloid stem...

Mechanism of butyrate remodeled calcium signaling in NK cells reverses daratumumab resistance in multiple myeloma

Tingting Li, Yao Liu Nov 03, 2025 pp. 917-917 10.1182/blood-2025-917

Abstract Background Daratumumab (Dara), a first-in-class anti-CD38 monoclonal antibody, is pivotal in multiple myeloma (MM) treatment. Never...

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Britten Gordon, Lillian Cool, Elizabeth Muhowski et al. Nov 03, 2025 pp. 1532-1532 10.1182/blood-2025-1532

Abstract Background: Treatment of CLL has been transformed by targeted therapies including inhibitors of Bruton's tyrosine kinase (BTKi). Cu...

Refined elderly comorbidity index is highly predictive of post-transplant survival in older adults with Acute Myeloid Leukemia and myelodysplastic syndrome

Fnu Amisha, Corbin Wright, Sean Haney et al. Nov 03, 2025 pp. 6076-6076 10.1182/blood-2025-6076

Abstract Background: Allogeneic hematopoietic cell transplantation (HCT) is the only curative option for most adults with acute myeloid leuk...

Neutrophil-lymphocyte and platelet-lymphocyte ratios as predictors of atherosclerotic thrombotic risk in patients with myelofibrosis

Veronica Vecchio, Emma Cacciola, Rossella Rosari Cacciola Nov 03, 2025 pp. 7332-7332 10.1182/blood-2025-7332

Abstract Myelofibrosis (MF) isa chronic myeloproliferative neoplasm associated with risk of atherosclerotic cardiovascular disease (ASCVD),...

Potential paradoxical hemostatic function of ADAMTS13 by enhancing collagen-induced platelet aggregation and activation

Huang Dong, X. Long Zheng Nov 03, 2025 pp. 4796-4796 10.1182/blood-2025-4796

Abstract Background: ADAMTS13 is an anti-thrombotic metalloenzyme that cleaves ultra large von Willebrand factor (VWF) released from endothe...

High treatment compliance and tolerability with fitusiran antithrombin-based dose regimen in people with hemophilia A or B, with or without inhibitors: ATLAS-OLE study

Mindy Simpson, Chia-Yau Chang, Kaan Kavakli et al. Nov 03, 2025 pp. 1298-1298 10.1182/blood-2025-1298

Abstract Background Hemophilia A (HB) and B (HB) are rare, inherited bleeding disorders characterized by a deficiency of clotting factors VI...

Toward precision pathology: Deep learning supported fibrosis grading augments performance of international hematopathologists in a large real-world cohort

Timothy Ebsworth, Sharon Ruane, Neha Bhardwaj et al. Nov 03, 2025 pp. 4335-4335 10.1182/blood-2025-4335

Abstract Introduction Evaluation of bone marrow fibrosis is essential in the assessment of newly diagnosed hematological...

Burden of Hodgkin lymphoma from 1990 to 2021 and modelled projection to 2050

Weili Wang, shensui li, JiShi Wang Nov 03, 2025 pp. 1848-1848 10.1182/blood-2025-1848

Abstract Background: Hodgkin lymphoma (HL) represents a significant malignancy, yet comprehensive data on its epidemiological evolution are...

When pregnancy, HIT, and stroke collide: Navigating complex thrombotic care in a community-based setting

Marco Herrera Quijano, Pedrom Farid, Andrea Cervi Nov 03, 2025 pp. 6670-6670 10.1182/blood-2025-6670

Abstract Background: Heparin-induced thrombocytopenia (HIT) is an infrequent but life-threatening complication of heparin exposure, occurrin...

Genetic analysis of B and T cell subsets from CLL patients prior to and at Richter's transformation

Sutapa Sinha, Panwen Wang, Hugues Sicotte et al. Nov 03, 2025 pp. 2099-2099 10.1182/blood-2025-2099

Abstract Introduction: A subset of patients with chronic lymphocytic leukemia (CLL) experiences disease progression from CLL to Richter tran...

Short-duration blinatumomab for residual disease eradication as a bridge to transplant in B-ALL: Pediatric and adult outcomes in a resource-limited context

Paulo Ugarte-Peláez, Julia Esther Colunga-Pedraza, Francisco Rubio et al. Nov 03, 2025 pp. 5135-5135 10.1182/blood-2025-5135

Abstract Background Blinatumomab is considered a standard of care for patients with B-cell acute lymphoblastic leukemia (B-ALL) and measurab...

Early methotrexate level thresholds predictive of acute kidney injury in patients with b cell lymphomas receiving high-dose methotrexate

Shazia Nakhoda, Farsha Rizwan, Rachel Thomas et al. Nov 03, 2025 pp. 4401-4401 10.1182/blood-2025-4401

Abstract Background: Methotrexate (MTX) induced acute kidney injury (AKI) occurs in 9% of patients (pts) receiving high dose (HD) methotrexa...

Asciminib and pregnancy in CML: Preliminary human data and clinical implications from 47 reported outcomes

Elisabetta Abruzzese, Ekaterina Chelysheva, Delphine Rea et al. Nov 03, 2025 pp. 5566-5566 10.1182/blood-2025-5566

Abstract Asciminib (ASC) is a first-in-class allosteric BCR::ABL1 tyrosine kinase inhibitor (TKI), specifically targeting the myristoyl pock...

Superior disease-free survival of allogeneic hematopoietic stem cell transplantation in elderly patients with hematological malignancies in complete remission by reduced-intensity or myeloablative conditioning

Yongqiang Zhao, Fang Fang, Yanzhi Song et al. Nov 03, 2025 pp. 4281-4281 10.1182/blood-2025-4281

Abstract Introduction: The prognosis of elderly patients with hematological malignancies by chemotherapy is usually poor. Allogeneic hematop...

Etiologies and clinical predictors of pediatric eosinophilia: A retrospective analysis from a tertiary care center

Henna Butt, Pallavi Dwivedi, Blachy Davila Saldana et al. Nov 03, 2025 pp. 6554-6554 10.1182/blood-2025-6554

Abstract Background: Eosinophilia in pediatric patients encompasses a broad spectrum of etiologies, ranging from allergic disorders to hemat...

Fus::ERG fusion represents adverse-plus risk group in AML patients: Evidence from a registry-based matched cohort Study

Yi-Han Yang, Meng Lv, Jia Chen et al. Nov 03, 2025 pp. 1706-1706 10.1182/blood-2025-1706

Abstract Background The Allo-HCT refined ELN 2022 classification identifies Adverse-Plus acute myeloid leukemia (AML) as the highest-risk su...

Effect of prior CD19-directed monoclonal antibody exposure on outcomes in patients subsequently treated with CD19 targeting CAR-T therapy: A multicenter propensity score matched retrospective cohort study

Shanawar Waris, Muqtasid Khan, Nanda Siva et al. Nov 03, 2025 pp. 4560-4560 10.1182/blood-2025-4560

Abstract Background CD19 is a transmembrane glycoprotein expressed throughout B-cell development and is preserved in most B-Cell malignancie...

Anti-platelet factor 4 antibodies in MGUS-related thrombosis

Adam Kanack, Noah Splinter, Damon Houghton et al. Nov 03, 2025 pp. 1321-1321 10.1182/blood-2025-1321

Abstract Introduction: Monoclonal gammopathy of thrombotic significance (MGTS) is a recently recognized thrombophilia where monoclonal plate...

CD62L enrichment achieves robust expansion and memory phenotype post-infusion in patients with LBCL treated with rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate

Akil Merchant, Ben Harris, Lora Zhao et al. Nov 03, 2025 pp. 501-501 10.1182/blood-2025-501

Abstract Background: Durable complete response remains the therapeutic goal when treating patients with large B-cell lymphoma (LBCL) with ch...

Cardiovascular outcomes of patients transitioned from ibrutinib to an alternate bruton tyrosine kinase inhibitor for hypertension and/or cardiovascular adverse events

Emily Tomasulo, Emeline Chong, Evani Patel et al. Nov 03, 2025 pp. 5680-5680 10.1182/blood-2025-5680

Abstract Introduction: Bruton tyrosine kinase inhibitors (BTKi) are highly efficacious oral agents FDA-approved for treatment of specific B-...

Upfront comprehensive donor search overcomes the impact of poor search prognosis, irrespective of racial background

Fei Fang, Ryan Vethanayagam, Karen Sherwood et al. Nov 03, 2025 pp. 6212-6212 10.1182/blood-2025-6212

Abstract Introduction: Access to suitably matched donors remains a major barrier to allogeneic hematopoietic cell transplantation (HCT), par...

DNA methylation episignature as a novel diagnostic tool for diamond-blackfan anemia

Paola Quarello, Karim Karimi, Slavica Trajkova et al. Nov 03, 2025 pp. 4673-4673 10.1182/blood-2025-4673

Abstract Background Diamond-Blackfan anemia syndrome (DBAS) is a rare inherited bone marrow failure syndrome (IBMFS) characterized by impair...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page